Tempus AI's stock soared 5.11% in pre-market trading on Thursday.
The surge follows news that Cathie Wood-led Ark Invest purchased 25,910 shares of the company, amounting to an investment of approximately $1.2 million, through its ARK Genomic Revolution ETF on Wednesday.
Investor sentiment was further bolstered by Tempus AI's strong first-quarter financial results, which showed revenue of $348.12 million, up 36.1% year-over-year and slightly above analyst expectations. The company also reported a narrower-than-expected loss and raised its full-year 2026 revenue outlook to between $1.59 billion and $1.60 billion, projecting adjusted EBITDA of approximately $65 million as demand for its AI-powered diagnostics platform continues to expand.